To describe serum acetaminophen-cysteine adduct (an experimental biomarker of acetaminophen exposure) concentrations following hepatic embolization in patients taking therapeutic doses of acetaminophen three days before the procedure
This study aims to describe protein adduct (an experimental biomarker of acetaminophen exposure) concentrations in patients taking therapeutic doses of acetaminophen who develop a liver injury from a cause other than acetaminophen.
Adult patients undergoing portal vein or bland embolization for the treatment of metastatic liver tumor; no known hypersensitivity or allergy to acetaminophen
Detailed Eligibility: Patients are not eligible with: known cirrhosis; history of moderate to severe anemia; currently taking warfarin, isoniazid, and disulfiram; weigh less than or equal to 50kg, pregnant or breastfeeding, and currently enrolled in a clinical trial
IV - Research Studies occurring after FDA has approved a drug for marketing. These studies gather additional information about a drug's safety, efficacy, or optimal use.
Denver Health and Hospital Authority
University of Colorado Hospital
Kennon Heard, MD
Protocol Number: 16-0031
More information available at ClinicalTrials.gov: NCT02911961
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers